Cargando…
Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas
INTRODUCTION: Aggressive pituitary adenomas (APAs) are, by definition, resistant to optimal multimodality therapy. The challenge lies in their early recognition and timely management. Temozolomide is increasingly being used in patients with APAs, but evidence supporting a favorable response with ear...
Autores principales: | Das, Liza, Gupta, Nidhi, Dutta, Pinaki, Walia, Rama, Vaiphei, Kim, Rai, Ashutosh, Radotra, Bishan Dass, Gupta, Kirti, Sreedharanunni, Sreejesh, Ahuja, Chirag Kamal, Bhansali, Anil, Tripathi, Manjul, Sood, Ridhi, Dhandapani, Sivashanmugam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718901/ https://www.ncbi.nlm.nih.gov/pubmed/34975752 http://dx.doi.org/10.3389/fendo.2021.774686 |
Ejemplares similares
-
Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas
por: Rai, Ashutosh, et al.
Publicado: (2021) -
Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes
por: Das, Liza, et al.
Publicado: (2021) -
The outcome of TSHoma from a tertiary care institute in India
por: Dutta, Aditya, et al.
Publicado: (2021) -
Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence
por: Das, Liza, et al.
Publicado: (2021) -
Outcomes in pituitary adenoma causing acromegaly following endoscopic endonasal transsphenoidal surgery
por: Chhabra, Rajesh, et al.
Publicado: (2022)